HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

4-hydroxycyclophosphamide

primary activation metabolite of cyclophosphamide; RN given refers to cpd without isomeric designation
Also Known As:
4-hydroxycyclophosphamide, (cis)-isomer; 4-hydroxycyclophosphamide, (trans)-isomer; NSC 196562; 2-(bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorin-4-ol 2-oxide
Networked: 25 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Joy, Melanie S: 2 articles (07/2013 - 09/2012)
2. Dooley, Mary Anne: 2 articles (07/2013 - 09/2012)
3. Ma, Jie: 2 articles (04/2011 - 01/2009)
4. Waxman, David J: 2 articles (04/2011 - 01/2009)
5. Jang, So Yoon: 1 article (07/2013)
6. Brouwer, Kim L R: 1 article (09/2012)
7. Blaisdell, Joyce: 1 article (09/2012)
8. Wang, Jinzhao: 1 article (09/2012)
9. La, Mary: 1 article (09/2012)
10. Hu, Yichun: 1 article (09/2012)

Related Diseases

1. Breast Neoplasms (Breast Cancer)
11/01/1999 - "This study investigated the pharmacokinetics of cyclophosphamide (CP) and its main metabolite 4-hydroxycyclophosphamide (4-OH-CP) in patients with breast cancer undergoing high dose chemotherapy prior to autologous stem cell transplantation. "
05/01/1996 - "Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients."
05/01/1996 - "The aim of this study was to investigate the covariance between the pharmacokinetics of the three components of the FEC regimen, epirubicin (EPI), fluorouracil (5-FU), and the cyclophosphamide (CP) metabolite 4-hydroxycyclophosphamide (4-OHCP), in breast cancer patients. "
05/19/2004 - "Consistent synergistic interactions of trastuzumab plus carboplatin, 4-hydroxycyclophosphamide, docetaxel, or vinorelbine across a wide range of clinically relevant concentrations in HER2-overexpressing breast cancer cells indicate that these are rational combinations to test in human clinical trials."
05/19/2004 - "At a wide range of clinically achievable drug concentrations, synergistic interactions were observed in all four breast cancer cell lines for trastuzumab plus carboplatin (mean combination index values ranged from 0.32 [P<.001] to 0.53 [P<.001]), 4-hydroxycyclophosphamide (mean combination index values ranged from 0.38 [P<.001] to 0.73 [P =.010]), docetaxel (mean combination index values ranged from 0.30 [P<.001] to 0.62 [P<.001]), and vinorelbine (mean combination index values ranged from 0.24 [P<.001] to 0.78 [P<.034]). "
2. Systemic Lupus Erythematosus (Libman-Sacks Disease)
3. Neoplasms (Cancer)
4. Ascites
5. Multiple Myeloma

Related Drugs and Biologics

1. Cyclophosphamide (Cytoxan)
2. Carboplatin (JM8)
3. Epirubicin (Ellence)
4. Fluorouracil (Carac)
5. trastuzumab (Herceptin)
6. docetaxel (Taxotere)
7. vinorelbine (Navelbine)
8. phosphoramide mustard
9. Cisplatin (Platino)
10. axitinib (AG 013736)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Stem Cell Transplantation
3. Heterologous Transplantation (Xenotransplantation)